AjmalineCAS# 4360-12-7 |
- (+)-Isoajmaline
Catalog No.:BCN3425
CAS No.:6989-79-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 4360-12-7 | SDF | Download SDF |
| PubChem ID | 6325117 | Appearance | Powder |
| Formula | C20H26N2O2 | M.Wt | 326.4 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (306.34 mM) *"≥" means soluble, but saturation unknown. | ||
| SMILES | CCC1C2CC3C4C5(CC(C2C5O)N3C1O)C6=CC=CC=C6N4C | ||
| Standard InChIKey | CJDRUOGAGYHKKD-QFTSDIPNSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Ajmaline is a class Ia anti-arrhythmic compound that is widely used for the diagnosis of Brugada syndrome and the acute treatment of atrial or ventricular tachycardia. 2. Ajmaline inhibits cardiac Kv1.5 and Kv4.3 channels at therapeutic concentrations. |
| Targets | Potassium Channel |
Ajmaline Dilution Calculator
Ajmaline Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0637 mL | 15.3186 mL | 30.6373 mL | 61.2745 mL | 76.5931 mL |
| 5 mM | 0.6127 mL | 3.0637 mL | 6.1275 mL | 12.2549 mL | 15.3186 mL |
| 10 mM | 0.3064 mL | 1.5319 mL | 3.0637 mL | 6.1275 mL | 7.6593 mL |
| 50 mM | 0.0613 mL | 0.3064 mL | 0.6127 mL | 1.2255 mL | 1.5319 mL |
| 100 mM | 0.0306 mL | 0.1532 mL | 0.3064 mL | 0.6127 mL | 0.7659 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Fangchinoline
Catalog No.:BCN5956
CAS No.:436-77-1
- Diffractic Acid
Catalog No.:BCN8506
CAS No.:436-32-8
- (-)-Curine
Catalog No.:BCN2673
CAS No.:436-05-5
- 5-Hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
Catalog No.:BCC8350
CAS No.:4354-76-1
- H-Arg(Tos)-OH
Catalog No.:BCC2867
CAS No.:4353-32-6
- L-5-Hydroxytryptophan
Catalog No.:BCC8106
CAS No.:4350-09-8
- K 41498
Catalog No.:BCC5867
CAS No.:434938-41-7
- Dacarbazine
Catalog No.:BCC1174
CAS No.:4342-03-4
- Nandrolone
Catalog No.:BCC9086
CAS No.:434-22-0
- Lithocholic Acid
Catalog No.:BCC3805
CAS No.:434-13-9
- Oxymetholone
Catalog No.:BCC4692
CAS No.:434-07-1
- Methenolone acetate
Catalog No.:BCC9028
CAS No.:434-05-9
- JKC 363
Catalog No.:BCC6022
CAS No.:436083-30-6
- Kobe0065
Catalog No.:BCC5290
CAS No.:436133-68-5
- Tetrodotoxin
Catalog No.:BCN1035
CAS No.:4368-28-9
- MRS 2365
Catalog No.:BCC5879
CAS No.:436847-09-5
- Gentisin
Catalog No.:BCN7518
CAS No.:437-50-3
- Genkwanin
Catalog No.:BCN5488
CAS No.:437-64-9
- Xanthinol nicotinate
Catalog No.:BCC9191
CAS No.:437-74-1
- Crategolic acid
Catalog No.:BCN5487
CAS No.:4373-41-5
- Salinosporamide A (NPI-0052, Marizomib)
Catalog No.:BCC2094
CAS No.:437742-34-2
- H-Thr(tBu)-OH
Catalog No.:BCC3106
CAS No.:4378-13-6
- 4-(4-Aminophenyl)morpholin-3-one
Catalog No.:BCC8650
CAS No.:438056-69-0
- SMI-4a
Catalog No.:BCC2233
CAS No.:438190-29-5
Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action.[Pubmed:23832378]
Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):991-9.
Ajmaline is a class Ia anti-arrhythmic compound that is widely used for the diagnosis of Brugada syndrome and the acute treatment of atrial or ventricular tachycardia. For Ajmaline, inhibitory effects on a variety of cardiac K(+) channels have been observed, including cardiac Kv1 and Kv4 channels. However, the exact pharmacological properties of channel blockade have not yet been addressed adequately. Using two different expression systems, we analysed pharmacological effects of Ajmaline on the potassium channels Kv1.5 and Kv4.3 underlying cardiac I Kur and I to current, respectively. When expressed in a mammalian cell line, we find that Ajmaline inhibits Kv1.5 and Kv4.3 with an IC50 of 1.70 and 2.66 muM, respectively. Pharmacological properties were further analysed using the Xenopus expression system. We find that Ajmaline is an open channel inhibitor of cardiac Kv1.5 and Kv4.3 channels. Whereas Ajmaline results in a mild leftward shift of Kv1.5 activation curve, no significant effect on Kv4.3 channel activation could be observed. Ajmaline did not significantly affect channel inactivation kinetics. Onset of block was fast. For Kv4.3 channels, no significant effect on recovery from inactivation or channel deactivation could be observed. Furthermore, there was no use-dependence of block. Taken together, we show that Ajmaline inhibits cardiac Kv1.5 and Kv4.3 channels at therapeutic concentrations. These data add to the current understanding of the electrophysiological basis of anti-arrhythmic action of Ajmaline.
